Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

FDA Approves Akynzeo for Chemo-Related Nausea, Vomiting

October 10, 2014
By Ian Ingram
Article

The FDA has approved combined netupitant and palonosetron (Akynzeo) for the treatment of chemotherapy-related nausea and vomiting in patients with cancer.

Netupitant prevents nausea/vomiting during the acute and delayed phases.

Earlier today the US Food and Drug Administration (FDA) approved the combination of netupitant and palonosetron (Akynzeo) for treating cancer patients experiencing chemotherapy-related nausea and vomiting.

The new drug combines two anti-emetics-a new agent, netupitant, and palonosetron, an oral drug first approved in 2008 for preventing chemo-related nausea and vomiting during the acute phase. Netupitant helps prevent nausea and vomiting during the delayed phase, as well as the acute phase.

“Supportive care products, such as Akynzeo, help ease the nausea and vomiting patients may experience as a side effect of cancer chemotherapy,” said Julie Beitz, MD, director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research, in a press release.

The two randomized trials that led to the approval of the netupitant/palonosetron combination included 1,720 patients who were receiving chemotherapy. Patients were assigned to either single-agent palonosetron or the netupitant/palonosetron combination.

The trials looked at the effectiveness at preventing chemo-related nausea/vomiting during the acute, delayed, and overall phases. The combination drug outperformed palonosetron alone in all three phases.

Data from the first trial showed that during the acute phase 98.5% of patients on the doublet therapy did not experience nausea and vomiting or require rescue medication compared with 89.7% of patients receiving palonosetron alone.

In the delayed phase 90.4% of patients on netupitant/palonosetron did not experience nausea/vomiting vs 80.1% for palonosetron alone.

During the overall phase 89.6% of patients on the doublet therapy did not experience nausea and vomiting vs 76.5% for palonosetron alone. Similar results were seen in the second trial.

Common adverse events experienced by patients who received netupitant/palonosetron were fatigue, constipation, dyspepsia, headaches, and asthenia.

Recent Videos
Acupuncture
Related Content
Advertisement

Complete responses were numerically higher without significance in standard triple antiemetic therapy with olanzapine vs placebo.

Adding Olanzapine to Antiemetic Therapy May Help With CINV Incidence

Roman Fabbricatore
August 4th 2024
Article

Complete responses were numerically higher without significance in standard triple antiemetic therapy with olanzapine vs placebo.


Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.

Oncology On-The-Go Podcast: Nursing-Led Palliative Care in Advanced Cancer

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN
May 15th 2023
Podcast

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.


Incorporating nursing-led palliative care may help to improve advanced care planning among those with advanced cancer, especially those without access to specialty palliative care.

Nursing-Led Palliative Cancer Care May Improve Advanced Care Planning

Hayley Virgil
April 13th 2023
Article

Incorporating nursing-led palliative care may help to improve advanced care planning among those with advanced cancer, especially those without access to specialty palliative care.


Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology

Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology

Dori Beeler, PhD;Xin Shelley Wang, MD, MPH;Viraj A. Master, MD, PhD
September 20th 2022
Podcast

Authors Dori Beeler, PhD; Shelley Wang, MD, MPH; and Viraj A. Master, MD, PhD, spoke with CancerNetwork® about a review article on cancer-related fatigue published in the journal ONCOLOGY®.


One in 3 nurses do not feel emotionally health, a large number of whom have experienced trauma due to the COVID-19 pandemic and no longer wish to be in their job position.

Emotional Health of Nurses Appears Continues to be Severely Impacted by the COVID-19 Pandemic, Survey Says

Lindsay Fischer
November 27th 2021
Article

One in 3 nurses do not feel emotionally health, a large number of whom have experienced trauma due to the COVID-19 pandemic and no longer wish to be in their job position.


Investigators have identified a gap in end-of-life care among patients with cancer who are dual eligible for Medicare and Medicaid.

Gap in End-of-Life Cancer Care Observed Among Those Eligible for Both Medicare and Medicaid

Lindsay Fischer
November 26th 2021
Article

Investigators have identified a gap in end-of-life care among patients with cancer who are dual eligible for Medicare and Medicaid.

Related Content
Advertisement

Complete responses were numerically higher without significance in standard triple antiemetic therapy with olanzapine vs placebo.

Adding Olanzapine to Antiemetic Therapy May Help With CINV Incidence

Roman Fabbricatore
August 4th 2024
Article

Complete responses were numerically higher without significance in standard triple antiemetic therapy with olanzapine vs placebo.


Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.

Oncology On-The-Go Podcast: Nursing-Led Palliative Care in Advanced Cancer

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN
May 15th 2023
Podcast

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.


Incorporating nursing-led palliative care may help to improve advanced care planning among those with advanced cancer, especially those without access to specialty palliative care.

Nursing-Led Palliative Cancer Care May Improve Advanced Care Planning

Hayley Virgil
April 13th 2023
Article

Incorporating nursing-led palliative care may help to improve advanced care planning among those with advanced cancer, especially those without access to specialty palliative care.


Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology

Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology

Dori Beeler, PhD;Xin Shelley Wang, MD, MPH;Viraj A. Master, MD, PhD
September 20th 2022
Podcast

Authors Dori Beeler, PhD; Shelley Wang, MD, MPH; and Viraj A. Master, MD, PhD, spoke with CancerNetwork® about a review article on cancer-related fatigue published in the journal ONCOLOGY®.


One in 3 nurses do not feel emotionally health, a large number of whom have experienced trauma due to the COVID-19 pandemic and no longer wish to be in their job position.

Emotional Health of Nurses Appears Continues to be Severely Impacted by the COVID-19 Pandemic, Survey Says

Lindsay Fischer
November 27th 2021
Article

One in 3 nurses do not feel emotionally health, a large number of whom have experienced trauma due to the COVID-19 pandemic and no longer wish to be in their job position.


Investigators have identified a gap in end-of-life care among patients with cancer who are dual eligible for Medicare and Medicaid.

Gap in End-of-Life Cancer Care Observed Among Those Eligible for Both Medicare and Medicaid

Lindsay Fischer
November 26th 2021
Article

Investigators have identified a gap in end-of-life care among patients with cancer who are dual eligible for Medicare and Medicaid.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.